MiMedx Group, Inc. MDXG

Updated: 9 Aug 2026

NASDAQ | Biotech | Regenerative medicine and wound care

No signal published yet

We already track MiMedx Group and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow MiMedx Group free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Regenerative medicine and wound care
We're already tracking MiMedx Group, Inc. — here are the latest events we've registered

Recent News

  • On July 29, 2026, MiMedx reported its second-quarter 2026 financial results with net sales of $64.4 million. On the same date, the company announced a definitive agreement to acquire Sanara MedTech in a transaction valued at approximately $350 million. The acquisition will be funded through a mix of cash and stock to expand MiMedx's surgical portfolio.

What Firelda Watch includes for MiMedx Group, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of MiMedx Group, Inc. will be delivered in the same format.

Want to follow MiMedx Group, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow MiMedx Group free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

MiMedx Group, Inc. MDXG
MiMedx Group — follow and we'll monitor it
Follow MiMedx Group free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.